Abstract
Colorectal cancer is a type of cancer with increasing frequency, especially in developed countries. The stage of the disease at diagnosis is directly related to the prognosis, and the treatment approach is shaped by accurate staging. Magnetic resonance imaging (MRI) is prominent in evaluating the primary tumor due to its high soft tissue contrast. Although the sensitivity and specificity of fluorodeoxyglucose (FDG) positron emission tomography/computed tomography (PET/CT) are reported to be higher than those of CT, its accuracy is limited by benign colonic involvements and inflammation-related involvements. While its sensitivity remains low in nodal staging, mostly due to the resolution limit, its superiority over conventional methods in detecting distant metastases has been reported. FDG PET/CT has been shown to detect recurrence with very high accuracy, even in patients with low carcinoembryonic antigen levels at restaging. There are studies investigating the role of FDG PET/CT in predicting the pathological response to neoadjuvant therapy in many patients with rectal cancer, and diffusion-weighted MRI has generally been found to be superior. To overcome the current limitations of FDG PET/CT, new generation imaging methods such as fibroblast activation protein inhibitor PET are being developed.
References
1Bray F, Laversanne M, Sung H, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024;74:229-263.
2Cervantes A, Adam R, Roselló S, et al. Metastatic colorectal cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. Ann Oncol Off J Eur Soc Med Oncol. 2023;34:10-32.
3National Comprehensive Cancer Network. Colon Cancer. Version 2.2024.
4National Comprehensive Cancer Network. Rectal Cancer. Version 2.2024.
5Faletti R, Gatti M, Arezzo A, et al. Preoperative staging of rectal cancer using magnetic resonance imaging: comparison with pathological staging. Minerva Chir. 2018;73:13-19.
6Ye Y, Liu T, Lu L, et al. Pre-operative TNM staging of primary colorectal cancer by (18)F-FDG PET-CT or PET: a meta-analysis including 2283 patients. Int J Clin Exp Med. 2015;8:21773-21785.
7Abdel-Nabi H, Doerr RJ, Lamonica DM, et al. Staging of primary colorectal carcinomas with fluorine-18 fluorodeoxyglucose whole-body PET: correlation with histopathologic and CT findings. Radiology. 1998;206:755-760.
8Kantorová I, Lipská L, Bêlohlávek O, Visokai V, Trubaĉ M, Schneiderová M. Routine (18)F-FDG PET preoperative staging of colorectal cancer: comparison with conventional staging and its impact on treatment decision making. J Nucl Med. 2003;44:1784-1788.
9Wnorowski AM, Menias CO, Pickhardt PJ, Kim DH, Hara AK, Lubner MG. Mucin-containing rectal carcinomas: Overview of unique clinical and imaging features. Am J Roentgenol. 2019;213:26-34.
10dos Anjos DA, Habr-Gama A, Vailati BB, et al. 18F-FDG uptake by rectal cancer is similar in mucinous and nonmucinous histological subtypes. Ann Nucl Med. 2016;30:513-517.
11Kousgaard SJ, Gade M, Petersen LJ, et al. Incidental detection of colorectal lesions on (18) F-FDG-PET/CT is associated with high proportion of malignancy: A study in 549 patients. Endosc Int Open. 2020;8:E1725-E1731.
12Kotanagi H, Fukuoka T, Shibata Y, et al. The size of regional lymph nodes does not correlate with the presence or absence of metastasis in lymph nodes in rectal cancer. J Surg Oncol. 1993;54:252-254.
13Brown G, Richards CJ, Bourne MW, et al. Morphologic predictors of lymph node status in rectal cancer with use of high-spatial-resolution MR imaging with histopathologic comparison. Radiology. 2003;227:371-377.
14Borgheresi A, De Muzio F, Agostini A, et al. Lymph Nodes Evaluation in Rectal Cancer: Where Do We Stand and Future Perspective. J Clin Med. 2022;11:2599.
15Sasaki K, Kawasaki H, Sato M, et al. Impact of Fluorine-18 2-Fluoro-2-Deoxy-D-Glucose Uptake on Preoperative Positron Emission Tomography/Computed Tomography in the Lymph Nodes of Patients with Primary Colorectal Cancer. Dig Surg. 2017;34:60-67.
16Raman SP, Chen Y, Fishman EK. Evolution of imaging in rectal cancer: multimodality imaging with MDCT, MRI, and PET. J Gastrointest Oncol. 2015;6:172-184.
17Boanova LG, Altmayer S, Watte G, et al. Detection of Liver Lesions in Colorectal Cancer Patients Using (18)F-FDG PET/CT Dual-Time-Point Scan Imaging. Cancers (Basel). 2023;15:5403.
18Joyce DL, Wahl RL, Patel P V, et al. Preoperative positron emission tomography to evaluate potentially resectable hepatic colorectal metastases. Arch Surg. 2006;141:1220-1226; discussion 1227.
19Selzner M, Hany TF, Wildbrett P, McCormack L, Kadry Z, Clavien P-A. Does the novel PET/CT imaging modality impact on the treatment of patients with metastatic colorectal cancer of the liver? Ann Surg. 2004;240:1026-1027.
20Kekelidze M, D’Errico L, Pansini M, et al. Colorectal cancer: current imaging methods and future perspectives for the diagnosis, staging and therapeutic response evaluation. World J Gastroenterol. 2013;19:8502-8514.
21Sanli Y, Kuyumcu S, Ozkan ZG, et al. The utility of FDG-PET/CT as an effective tool for detecting recurrent colorectal cancer regardless of serum CEA levels. Ann Nucl Med. 2012;26:551-558.
22Huang Y-Y, Lee P-I, Liu M-C, et al. A General Cutoff Level Combined With Personalized Dynamic Change of Serum Carcinoembryonic Antigen Can Suggest Timely Use of FDG PET for Early Detection of Recurrent Colorectal Cancer. Clin Nucl Med. 2015;40:e465-e469.
23Dossa F, Chesney TR, Acuna SA, et al. A watch-and-wait approach for locally advanced rectal cancer after a clinical complete response following neoadjuvant chemoradiation: a systematic review and meta-analysis. lancet Gastroenterol Hepatol. 2017;2:501-513.
24Chadi SA, Malcomson L, Ensor J, et al. Factors affecting local regrowth after watch and wait for patients with a clinical complete response following chemoradiotherapy in rectal cancer (InterCoRe consortium): an individual participant data meta-analysis. Lancet Gastroenterol Hepatol. 2018;3:825-836.
25Lambregts DMJ, Vandecaveye V, Barbaro B, et al. Diffusion-weighted MRI for selection of complete responders after chemoradiation for locally advanced rectal cancer: a multicenter study. Ann Surg Oncol. 2011;18:2224-2231.
26Joye I, Deroose CM, Vandecaveye V, et al. The role of diffusion-weighted MRI and (18)F-FDG PET/CT in the prediction of pathologic complete response after radiochemotherapy for rectal cancer: a systematic review. Radiother Oncol. 2014;113:158-165.
27Zhang C, Tong J, Sun X, et al. 18F-FDG-PET evaluation of treatment response to neo-adjuvant therapy in patients with locally advanced rectal cancer: a meta-analysis. Int J Cancer. 2012;131:2604-2611.
28Zerizer I, Al-Nahhas A, Towey D, et al. The role of earlyF-FDG PET/CT in prediction of progression-free survival after Y radioembolization: comparison with RECIST and tumour density criteria. Eur J Nucl Med Mol Imaging. 2012;39:1391-1399.
29Shady W, Kishore S, Gavane S, et al. Metabolic tumor volume and total lesion glycolysis on FDG-PET/CT can predict overall survival after (90)Y radioembolization of colorectal liver metastases: A comparison with SUVmax, SUVpeak, and RECIST 1.0. Eur J Radiol. 2016;85:1224-1231.
30Fendler WP, Philippe Tiega DB, Ilhan H, et al. Validation of several SUV-based parameters derived from 18F-FDG PET for prediction of survival after SIRT of hepatic metastases from colorectal cancer. J Nucl Med. 2013;54:1202-1208.
31Soydal C, Kucuk ON, Gecim EI, et al. The prognostic value of quantitative parameters of 18F-FDG PET/CT in the evaluation of response to internal radiation therapy with yttrium-90 in patients with liver metastases of colorectal cancer. Nucl Med Commun. 2013;34:501-506.
32Weber M, Lam M, Chiesa C, et al. EANM procedure guideline for the treatment of liver cancer and liver metastases with intra-arterial radioactive compounds. Eur J Nucl Med Mol Imaging. 2022;49:1682-1699.
33Sagawa T, Sato Y, Nagashima H, et al. Hilar/mediastinal and cutaneous drug-induced sarcoidosis-like reaction associated with immune checkpoint inhibitors in metastatic colorectal cancer: a case report. Front Immunol. 2023;14:1203621.
34Aedma SK, Chidharla A, Kelting S, Kasi A. Oxaliplatin-associated sarcoid-like reaction masquerading as recurrent colon cancer. BMJ Case Rep. 2020;13:e229548.
35Gounaris I, Ahmad A. Capecitabine-induced cerebellar toxicity in a patient with metastatic colorectal cancer. J Oncol Pharm Pract. 2009;16:277-279.
36Chen J, Du F, Hu B, et al. Severe Cardiotoxicity in a Patient with Colorectal Cancer Treated with Bevacizumab. Anticancer Res. 2017;37:4557-4561.
37Siegel RL, Miller KD, Wagle NS, et al. Cancer statistics, 2023. CA Cancer J Clin. 2023;73:17-48.
38Hayman AV, Halverson AL. Anal carcinoma. Clin Scenar Surg Decis Mak Oper Tech. Published Online. 2024:226-228.
39Mahmud A, Poon R, Jonker D. PET imaging in anal canal cancer: a systematic review and meta-analysis. Br J Radiol. 2017;90:20170370.
40Sena Y, Matsumoto S, Silman C, et al. Physiological 18F-FDG uptake in the normal adult anal canal: evaluation by PET/CT. Ann Nucl Med. 2020;34:538-544.
41Vos D, Wang M, Ramaiya S, et al. Anorectal pathology in the HIV population: a guide for radiologists. Abdom Radiol (New York). 2022;47:1762-1774.
42Kim BS. The 18F-FDG PET/CT finding of a condyloma acuminata mimicking primary anorectal carcinoma in an HIV-infected patient. Clin Nucl Med. 2013;38(10):e402-e403.
43Mirshahvalad SA, Mesci A, Murad V, et al. [18F]-FDG PET in anal canal cancer: a systematic review and meta-analysis. Eur J Nucl Med Mol Imaging. 2023;51:258-277.
44Jones M, Hruby G, Solomon M, et al. The Role of FDG-PET in the Initial Staging and Response Assessment of Anal Cancer: A Systematic Review and Meta-analysis. Ann Surg Oncol. 2015;22:3574-3581.
45Cliffe H, Patel C, Prestwich R, et al. Radiotherapy response evaluation using FDG PET-CT-established and emerging applications. Br J Radiol. 2017;90:20160764.
46Bailleux C, Zwarthoed C, Evesque L, et al. Prognostic impact of post-treatment FDG PET/CT in anal canal cancer: A prospective study. Radiother Oncol J Eur Soc Ther Radiol Oncol. 2023;188:109905.
47Baum RP, Hertel A, Lorenz M, et al. 99Tcm-labelled anti-CEA monoclonal antibody for tumour immunoscintigraphy: first clinical results. Nucl Med Commun. 1989;10:345-352.
48Wong JYC, Yamauchi DM, Adhikarla V, et al. First-In-Human Pilot PET Immunoimaging Study of 64Cu-Anti-Carcinoembryonic Antigen Monoclonal Antibody (hT84.66-M5A) in Patients with Carcinoembryonic Antigen-Producing Cancers. Cancer Biother Radiopharm. 2022;38:26-37.
49Li L, Lin X, Wang L, et al. Immuno-PET of colorectal cancer with a CEA-targeted [68 Ga]Ga-nanobody: from bench to bedside. Eur J Nucl Med Mol Imaging. 2023;50:3735-3749.
50Schoffelen R, Boerman OC, Goldenberg DM, et al. Development of an imaging-guided CEA-pretargeted radionuclide treatment of advanced colorectal cancer: first clinical results. Br J Cancer. 2013;109:934-942.
51Fracasso PM, Burris H 3rd, Arquette MA, et al. A phase 1 escalating single-dose and weekly fixed-dose study of cetuximab: pharmacokinetic and pharmacodynamic rationale for dosing. Clin Cancer Res. 2007;13:986-993.
52Azzopardi N, Lecomte T, Ternant D, et al. Cetuximab pharmacokinetics influences progression-free survival of metastatic colorectal cancer patients. Clin Cancer Res. 2011;17:6329-6337.
53van Helden EJ, Elias SG, Gerritse SL, et al. [89Zr]Zr-cetuximab PET/CT as biomarker for cetuximab monotherapy in patients with RAS wild-type advanced colorectal cancer. Eur J Nucl Med Mol Imaging. 2020;47:849-859.
54Menke-van der Houven van Oordt CW, Gootjes EC, Huisman MC, et al. 89Zr-cetuximab PET imaging in patients with advanced colorectal cancer. Oncotarget. 2015;6:30384-30393.
55Lee TS, Song IH, Shin J Il, et al. PET Imaging Biomarkers of Anti-EGFR Immunotherapy in Esophageal Squamous Cell Carcinoma Models. Cells. 2018;7:187.
56Han Z-W, Lyv Z-W, Cui B, et al. The old CEACAMs find their new role in tumor immunotherapy. Invest New Drugs. 2020;38:1888-1898.
57Cuda TJ, Riddell AD, Liu C, et al. PET Imaging Quantifying (68)Ga-PSMA-11 Uptake in Metastatic Colorectal Cancer. J Nucl Med. 2020;61:1576-1579.
58Haffner MC, Kronberger IE, Ross JS, et al. Prostate-specific membrane antigen expression in the neovasculature of gastric and colorectal cancers. Hum Pathol. 2009;40:1754-1761.
59Nakajo M, Nakajo M, Kajiya Y, et al. Diagnostic performance ofF-fluorothymidine PET/CT for primary colorectal cancer and its lymph node metastasis: comparison with F-fluorodeoxyglucose PET/CT. Eur J Nucl Med Mol Imaging. 2013;40:1223-1232.
60Hong YS, Kim HO, Kim K, et al. 3’-Deoxy-3’-18F-fluorothymidine PET for the early prediction of response to leucovorin, 5-fluorouracil, and oxaliplatin therapy in patients with metastatic colorectal cancer. J Nucl Med. 2013;54:1209-1216.
61Erol Fenercioğlu Ö, Beyhan E, Şahin R, et al. The potential role of 68Ga-FAPİ-04 PET/CT for screening malignancy in suspected colonic lesions. Nucl Med Commun. 2023;44:896-899.
62Erol Fenercioğlu Ö, Yarikkaya E, Beyhan E, et al. Role of 68 Ga-FAPİ PET/CT in Screening Malignancy of Familial Adenomatous Polyposis. Clin Nucl Med. 2023;48:e141-e142.
63Chen L, Zhong X, Li L, et al. [68Ga]Ga-FAPİ-04 PET/CT on assessing Crohn’s disease intestinal lesions. Eur J Nucl Med Mol Imaging. 2023;50:1360-1370.
64Şahin E, Elboğa U, Çelen YZ, et at. Comparison of 68Ga-DOTA-FAPİ and 18FDG PET/CT imaging modalities in the detection of liver metastases in patients with gastrointestinal system cancer. Eur J Radiol. 2021;142:109867.
65Zhuang Z, Zhang Y, Yang X, et al. Head-to-head comparison of the diagnostic performance between (68)Ga-FAPİ-04 PET/CT and (18)F-FDG PET/CT in colorectal cancer: a systematic review and meta-analysis. Abdom Radiol (New York). Published online April 2024.
66Koerber SA, Staudinger F, Kratochwil C, et al. The role of 68ga-FAPİ pet/ct for patients with malignancies of the lower gastrointestinal tract: First clinical experience. J Nucl Med. 2020;61:1331-1336.
67He J, Wang Q, Zhang Y, et al. Preoperative prediction of regional lymph node metastasis of colorectal cancer based on 18F-FDG PET/CT and machine learning. Ann Nucl Med. 2021;35:617-627.
68Lv L, Xin B, Hao Y, et al. Radiomic analysis for predicting prognosis of colorectal cancer from preoperative 18F-FDG PET/CT. J Transl Med. 2022;20:66.
69Heringer VCCR, Mendes MCS, Amorim BJ, et al. Artıfıcıal Intellıgence To Evaluate Metabolıc Tumor Burden In Prımary Stagıng Of Rectal Cancer Wıth 18F-FDG PET/CT. Hematol Transfus Cell Ther. 2024;46:3-4.
